Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PT3 Oncology > colon and lung > Flashcards

colon and lung Flashcards

1
Q

colon cancer risk

A

1 in 25

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

colon cancer growth rate

A

slow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

risk factors of colon cancer

A
  • Family history 20%
  • IBD
  • lifestyle factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

life style risk factors for colon cancer

A
  • smoking
  • red/processed meats
  • alcohol
  • low physical activity
  • high BMI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

age to start colon cancer screening if no risk factors

A

50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

age to start colon cancer screening if FHx positive

A

40 or 10 years prior to relatives diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

age to start colon cancer screening if HNPCC

A

20-25

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

age to start colon cancer screening if FAP

A

puberty, 10-12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

age to start colon cancer screening if UC or CD

A

8 years after onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

two types of screening tools for colon cancer

A
  • flexible sigmoidoscopy

- total colonoscopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

flexible sigmoidoscopy features

A
  • removes polyps
  • 20 mins
  • no sedation
  • only examines 60% of colon
  • no biopsy
  • less bowel prep
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

total colonoscopy features

A

-examines whole bowel
-removes polyps
-can biopsy
-not as cost effective
invasive
-intense bowel prep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

factors that lead to mutation in colon cancer development

A
  • activation of Wnt
  • activation of EGFR and oncogenes
  • inactivation of tumor suppressors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

most common sites of metastasis for colon cancer

A

in order:

  • liver
  • lung
  • bone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

staging work up needed for colon cancer

A
  • CT or MRI
  • diagnostic colonoscopy
  • CBC and CMP
  • genetic testing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

important genetic tests for colon cancer

A
  • Ras
  • micro-satellite instability
  • mismatch repair

-UGT1A1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

curable stages of colon cancer

A

stage 1 - 3B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

general treatment for stage 0 and 1 colon cancer

A

surgery

surveillance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

general treatment for stage 2 colon cancer

A

surgery

adjuvant chemo?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

general treatment for stage 3 colon cancer

A

surgery?

adjuvant chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

general treatment for stage liver only metastasis in colon cancer

A
  • chemoembolization
  • hepatic arterial infusion chemo
  • surgery?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

general treatment for stage 4 colon cancer

A
  • palliative chemo

- surgery/radiation?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

treatment of choice for stages 1-3 of colon cancer

A

surgery

24
Q

what drug do we need to check UGT1A1 for

A

irinotecan

25
Q

adjuvant chemo for stage 3 colon cancer

A

5-FU/leucovorin

26
Q

adjuvant chemo options for high risk stage 3 or palliative colon cancer

A
  • FOLFOX +/- bevacizumab
  • FOLFOX +/- cetuximab/panitumumab
  • CAPEOX +/- bevacizumab
  • FOLFIRI + cetuximab/panitumumab
27
Q

duration of therapy for high risk stage 3 colon cancer

A

6 months

28
Q

duration of therapy for metastatic colon cancer

A

until progression or intolerance to therapy

29
Q

if patient progressed through FOLFOX and FOLFIRI OR can’t tolerate intense therapy, what can we use

A
  • MIS, MMR therapy

- PD-1 therapy (nivolumab/ pembrolizumab)

30
Q

drugs in mFOLFOX 6 + beva regimen and cycle length

A

-leucovorin
-oxaliplatin
-5-FU push and cont.
-Beva
14 day cycle, 12 cycles

31
Q

unique toxicity from oxaliplatin

A

laryngeal spasms when drinking something cold

32
Q

how leucovorin works in colon cancer

A

helps 5-FU bind and stay bound to thymidylate synthase

33
Q

monitoring for FOLFOX + Bev

A
  • bone marrow, especially platelets
  • renal/hepatic function
  • neurologic effects
  • vascular - VTE
  • wound healing
34
Q

minimum time between bevacizumab treatment and surgical procedures

A

28 days due to reduced healing

35
Q

side effects for FOLFOX + bevacizumab

A
  • fatigue
  • N/V/D
  • infection
  • laryngeal spasm/neuropathy
  • bruising, bleeding, clotting
36
Q

lifetime risk of lung cancer

A

1 in 15

37
Q

workup and staging of lung cancer

A
  • Hx and physical
  • symptoms (coughing blood)
  • cbc/cmp
  • PET-Ct or MRI
  • biopsy
  • ECOG
38
Q

ECOG scale for lung cancer

A 
0 = fully active
1 = restricted from strenuous activity, can do light work
2 = up and about >50%
3 = in bed or chair > 50%
4 = completely disabled
5 = dead
39
Q

ECOG scores we’re willing to treat aggressively

A

0-2

40
Q

general types of lung cancer

A
  • non-small cell lung cancer

- small cell lung cancer

41
Q

characteristics of small cell lung cancer

A
  • fast doubling time
  • high growth fraction
  • early development of metastasis
  • highly correlated with smoking
  • no effective means to screen
42
Q

most pts diagnosed with SCLC are in which stage

A

stage 4

43
Q

upside of treating SCLC

A
  • responsive to chemo
  • responsive to radiation
  • substantial improvement in QoL
44
Q

downside of treating SCLC

A
  • metastasis has usually already occurred
  • after initial treatment its usually resistant
  • abnormal secretions (ACh, prothrombotics)
45
Q

treatment plan for limited stage SCLC

A

chemo and radiotherapy to chest

46
Q

treatment plan for extensive stage SCLC

A

chemo alone

47
Q

chemo treatment for SCLC including cycle

A

etoposide and cisplatin/carboplatin

21 day cycle, 6 cycles

48
Q

characteristics of non-small cell lung cancer

A
  • moderate doubling time
  • low growth fraction
  • early development of metastasis
  • highly correlated with smoking
  • no effective means to screen
49
Q

staging of SCLC

A

1-3 confined to ipsilateral hemithorax

4 beyond ipsilateral hemithorax

50
Q

staging of NSCLC

A

1 - localized
2 - localized w/lymph
3 - invasion through lung
4 - distant spread

51
Q

chemotherapy strategy for early stage lung cancer

A

doublet therapy

52
Q

chemotherapy strategy for metastatic NSCLC

A

if we have agents that can be used for targeted therapy use the
otherwise doublet therapy if they can tolerate

53
Q

doublet therapy regimens for NSCLC

A
  • cisplatin + paclitaxel or gemcitabine or docetaxel

- carboplatin + paclitaxel

54
Q

mutations important in treatment of NSCLC

A

ALK
ROS1
KRAS
BRAF

55
Q

oncogene addiction

A

mutations that drive the neoplastic phenotype

PT3 Oncology (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions